Interleukin 2 in the treatment of acute leukemia

Leukemia Research

Volumn 22, Issue 12, 1998, Pages 1165-1170

  Blaise, Didier ^a   Maraninchi, Dominique ^a  

^a INSTITUT PAOLI CALMETTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2;

ACUTE LEUKEMIA; ADVANCED CANCER; BLOOD TOXICITY; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CARDIOTOXICITY; CLINICAL TRIAL; DRUG EFFICACY; GENE TRANSFER; HUMAN; LUNG TOXICITY; LYMPHOKINE ACTIVATED KILLER CELL; NEUROTOXICITY; PRIORITY JOURNAL; REVIEW;

EID: 0032423014     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(98)00115-5     Document Type: Article

References (29)

1. Foon K.A., Smalley R.V., Riggs C.W.et al. The role of immunotherapy in acute myelogenous leukemia. Arch Intern Med. 143:1983;1726.
2. Zittoun R.A., Mandelli F., Willemze R.E., De Witte T., Labar B., Resegotti L., Leoni F., Damasio E., Visani G., Papa G., Caronia F., Hayat M., Stryckmans P., Rotoli B., Leoni P., Peetermans M.E., Dardene M., Vegna M.L., Petti M.C., Solbu G., Suciu S. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. New Engl J Med. 332:1995;217.
3. Horowitz M.M., Gale R.P., Sondel P.M., Goldman J.M., Kersey J., Kolb H.J., Rimm A.A., Ringden O., Rozman C., Speck B., Truitt R.L., Zwaan F.E., Bortin M.M. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 75:1990;555.
4. Maraninchi D., Gluckman E., Blaise D., Guyotat D., Rio B., Pico J.L., Leblond V., Michallet M., Dreyfus F., Ifrah N., Bordigoni A. Impact of T-cell depletion on outcome of allogeneic bone marrow transplantation for standard risk leukaemias. The Lancet. 25:1987;175.
5. Blaise D., Olive D., Michallet M., Marit G., Leblond V., Maraninchi D. Impairment of leukaemia-free survival by addition of interleukin-2 receptor antibody to standard graft-versus-host prophylaxis. The Lancet. 345:1997;1144.
6. Kolb H.J., Schattenberg A., Goldman J.M.et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group of Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood. 56:1995;2041.
7. Fierro M.T., Xin-Sheng L., Lusso P., Bonferroni M., Matera L., Cesano A., Lista P., Arione R., Forni G., Foa R. In vitro and in vivo susceptibility of human leukemic cells to lymphokine activated killer activity. Leukemia. 2:1988;50.
8. Lotzova E., Savary C.A., Herberman R.B. Inhibition of clonogenic growth of fresh leukemia cells by unstimulated and IL-2 stimulated NK cells of normal donors. Leuk Res. 11:1987;1059.
9. Foa R. Interleukin 2 in the management of acute leukaemia. Br J Haematol. 92:1996;1.
10. Maraninchi D., Blaise D., Viens P., Brandely M., Olive D., Lopez M., Sainty D., Stoppa A.M., Reiffers J., Gratecos N., Bertau-Perez P., Mannoni P., Mawas C., Hercend T., Sebahoun G., Carcassonne Y. High-dose recombinant interleukin 2 and acute myeloid leukemias in relapse. Blood. 78(9):1991;2182.
11. Blaise D., Viens P., Olive D., Stoppa A.M., Gabert J., Pourreau C.N., Attal M., Gaspard M.H., Mannoni P., Jasmin C., Palmer P., Franks C., Michel G., Mawas C., Philip T., Maraninchi D. Recombinant interleukin-2 (rIL-2) after autologous bone marrow transplantation (BMT): a pilot study in 19 patients. Eur Cytokine Netw. 2(2):1991;121-129.
12. Blaise D., Olive D., Stoppa A.M., Viens P., Pourreau C., Lopez M., Attal M., Jasmin C., Monges G., Mawas C., Mannoni P., Palmer P., Franks C., Philips T., Maraninchi D. Hematologic and Immunologic effects of the systemic administration of recombinant Interleukin-2 after autologous bone marrow transplantation. Blood. 76(6):1990;1092.
13. Meloni G., Foa R., Vignetti M., Guarini A., Fenu S., Tosti A.G., Mandelli F. Interleukin-2 may induce prolonged remissions in advanced acute myelogenous leukemia. Blood. 84:1994;2158.
14. Soiffer R.J., Murray C., Gonin R., Ritz J. Effect of low dose interleukin-2 on disease relapse after T-cell depleted allogeneic bone marrow transplantation. Blood. 84:1994;964.
15. Blaise D., Attal M., Pico J.L., Reiffers J., Stoppa A.M., Bellanger C., Molina L., Nédellec G., Vernant J.P., Legros M., Gabus R., Huguet F., Brandelys M., Hercend T., Olive D., Maraninchi D. The use of sequential high dose recombinant interleukin-2 regimen after autologous bone marrow transplantation does not improve the disease transplanted in first complete remission. Leuk Lymphoma. 25:1997;469.
16. O'Brien D., Boughton B. High and low affinity IL-2 receptors on human leukaemic blasts cells. Br J Haematol. 76:1990;315.
17. Foa R., Caretto P., Fierro M.T.et al. Interleukin-2 does not promote the in vitro and in vivo proliferation and growth of human acute leukaemia cells of myeloid and lymphoid origin. Br J Haematol. 75:1990;34.
18. Lim S.H., Newland A.C., Kelsey S., Bell A., Offerman E., Rist C., Gozzard D., Bareford D., Smith M.P., Goldstone A.H. Continuous intravenous infusion of high dose recombinant interleukin-2 for acute myeloid leukaemia: a phase II study. Cancer Immunol Immunother. 34:1992;337.
19. Toze C.L., Barnett M.J., Klingemann H.G. Response of therapy-related myelodysplasia to low dose interleukin-2. Leukemia. 7:1993;463.
20. Olive D., Chambost H., Sainty D., Stoppa A.M., Blaise D., El Marsafy S., Brandely M., Mannoni P., Mawas C., Maraninchi D. Modification of leukemlic blasts cells induced by in vivo high dose recombinant interleukin-2. Leukemia. 8:1994;1230.
21. Foa R. Does interleukin-2 have a role in the management of acute leukemia? J Clin Oncol. 11(9):1993;1817.
22. Macdonald D., Jiang Y., Gordon A., Mahendra P., Oskam R., Palmer P., Franks C., Barret J. Recombinant interleukin-2 for acute myeloid leukemia in first complete remission: a pilot study. Leuk Res. 1:1990;967.
23. Weisdorf D.J., Anderson P.M., Blazar B.R., Uckun F.M., Kersey J.H., Ramsay N.K. Interleukin 2 immediately after autologous bone marrow transplantation for acute lymphoblastic leukemia: a phase I study. Transplantation. 55:1993;61.
24. Blaise D, Attal M, Reiffers J, Stoppa AM, Huguet F, Marit G, Molina L, Bellanger C, Pico JL, Gabus R, Brandely M, Hercend T, Maraninchi D. Randomized study of Interleukin 2 after autologous bone marrow transplantation in 130 patients with acute leukemia in first complete remission: results of a multicentric trial with a 5 year follow-up. 39th Annual Meeting for the American Society of Hematology (Decembre 5-9, San Diego, USA) 1997.
25. Benyunes M.C., Massumoto C., York A., Higuchi C.M., Buckner C.D., thompson J.A., Petersen F.B., Fefer A. Interleukin-2 with or without lymphokine-activated killer cells as consolidative immunotherapy after autologous bone marrow transplantation for acute myelogenous leukemia. Bone Marrow Transplant. 12:1993;159.
26. Hamon M.D., Prentice H.G., Gottlieb D.J., Macdonald I.D., Cunningham J.M., Smith O.P., Gilmore M., Gandhi L., Collis C. Preliminary report: Immunotherapy with Interleukin 2 after ABMT in AML. Bone Marrow Transplant. 11:1993;399.
27. Klingemann H.G., Eaves C.J., Barnett M.J., Eaves A.C., Hogge D.E., Nantel S.H., Reece E., Shepherd J.D., Sutherland H.J., Philips G.L. Transplantation of patients with high risk acute myeloid leukemia in first remission with autologous marrow cultured in interleukin-2 followed by interleukin-2 administration. Bone Marrow Transplant. 14:1994;389.
28. Charak B.S., Agah R., Brynes R.K.et al. Interleukin 2 and IL-2 activated bone marrow in transplantation: Evaluation from a clinical perspective. Bone Marrow Transplant. 9:1992;479.
29. Cignetti A., Guarini A., Carbone A., Forni M., Cronin K., Forni G., Gansbacher B., Foa R. Transduction of the IL2 gene into human acute leukemia cells: induction of tumor rejection without modifying cell proliferation and IL2 receptor expression. J Natl Cancer Inst. 86:1994;785.